The purpose of the Tissue Core (TC) is to help the facilitate the scientific needs of peer-reviewed. Cancer Center investigators by providing a collection of centralized services and technologies focused around high quality, richly-annotated human biospecimens. The TC is organized in four distinct operational sections that provide end-to-end biorepository services required for the collection, processing, annotation, storage and ultimate release of biospecimens. The TC-lntake &Acquisition section is responsible for the collection and initial annotation and de-identification of biospecimens for investigator driven and general banking protocols. The TC-Sample Processing Lab provides a wide variety of biospecimen processing services ranging from processing of blood to extraction of nucleic acids. The TC-Research Histology Services section supports CCSG investigators by offering basic histology services, research focused immunohistochemistry and construction of Tissue Microarray. The TC-Lifetime Cancer Screening operates as a Tissue Core satellite facility at the Center's Lifetime Cancer Screening and Prevention Center. The technical staff is responsible for operating and maintaining core instrumentation and technology. Over the last grant period, the Core established sophisticated, state-of-the-science technologies to support Immunohistochemistry (Ventana Discovery Automated System), automated, high-throughput nucleic acid extraction systems, (Qiagen) and most recently a Shared Instrumentation Grant funded automated freezer system. A new biospecimen inventory management system (LabVantage Biobanking) was also launched. The new LabVantage Biobanking system provides centralized comprehensive sample management, consent verification and biospecimen de-identification allowing the core to effectively serve as an institutional Honest Broker. Access to biospecimens and Tissue Core services are governed by regularly updated biospecimen collection and utilization policies and well-defined chargeback mechanism. Collectively, all four TC sections are heavily utilized by all 5 research programs and provide support for over 90 investigator-initiated protocols. The Core requests CCSG Support of $400,966, which is 24% of its operational budget. Over 75% of total users are Moffitt members and peer-reviewed.

Public Health Relevance

With highly trained staff, the Tissue Core provides Moffitt members with a state-of-the-art centralized biorepository, processing and histology services to conduct extensive cancer research. The significant investment in infrastructure as well as state of the art equipment and instrumentation provides a large and efficient biospecimen resource for Moffitt members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-16
Application #
8613459
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$201,088
Indirect Cost
$81,748
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen et al. (2016) Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5:294-303
Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y et al. (2016) Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 25:3600-3612
Weber, Jeffrey; Gibney, Geoffrey; Kudchadkar, Ragini et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4:345-53
Schabath, Matthew B; Massion, Pierre P; Thompson, Zachary J et al. (2016) Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 11:e0159880
Turner, Joel G; Dawson, Jana L; Grant, Steven et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 9:73
Haake, Scott M; Li, Jiannong; Bai, Yun et al. (2016) Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res :
Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2016) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol :
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2016) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol :
Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029
Robinson, Lary A; Jaing, Crystal J; Pierce Campbell, Christine et al. (2016) Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung. Br J Cancer 115:497-504

Showing the most recent 10 out of 974 publications